Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 13/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.83 |
| ▸ | HPGD | P15428 | 6/20 | 0.83 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.75 |
| ▸ | GAA | P10253 | 3/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | PLEC | Q15149 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4072392 | 0.92 | KDM4E (0.83) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL4074554 | 0.89 | KDM4E (0.79) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL4080510 | 0.83 | ALDH1A1 (0.81) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL5453521 | 0.81 | POLB (0.78) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL4074094 | 0.76 | KDM4E (0.61) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL4070804 | 0.74 | KDM4E (0.92) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL4936946 | 0.73 | SMN1; SMN2 (0.77) | GAA | |
| SCHEMBL4075930 | 0.73 | POLB (0.85) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL6321588 | 0.72 | TAS2R14 (0.69) | — | |
| SCHEMBL4071631 | 0.72 | KDM4E (0.70) | KDM4EALDH1A1HPGDHSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2040711-A2 | 2-OXO-1,2-DIHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS | Amphora Discovery Corporation (US) | 2009-04-01 | — | — | EP | claimed |
| US-20070287706-A1 | Certain substituted quinolones, compositions, and uses thereof | AGRIUS GROUP, LLC. | 2007-12-13 | — | — | US | claimed |
| WO-2007136592-A2 | 2-0X0-L,2-DIHYDR0QUIN0LINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS | AMPHORA DISCOVERY CORPORATION (US) | 2007-11-29 | — | — | WO | claimed |
| EP-2040711-A2 | 2-OXO-1,2-DIHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS | Amphora Discovery Corporation (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20070287706-A1 | Certain substituted quinolones, compositions, and uses thereof | AGRIUS GROUP, LLC. | 2007-12-13 | — | — | US | disclosed |
| WO-2007136592-A2 | 2-0X0-L,2-DIHYDR0QUIN0LINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS | AMPHORA DISCOVERY CORPORATION (US) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287706-A1 | Certain substituted quinolones, compositions, and uses thereof | ABCG2, ATP5ME, ATP5MG | KDM4E 2403/4885ALDH1A1 1055/4885HPGD 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.